Topical Cyanoacrylates Market Expected to Receive Greater Traction As Manufacturers’ Contribution Swells

 Topical Cyanoacrylates Market Summary

The global topical cyanoacrylates market size was estimated at USD 97.5 million in 2024, and is projected to reach USD 160.2 million by 2033, growing at a CAGR of 5.65% from 2025 to 2033. The market growth is primarily driven by increasing demand for advanced wound closure and tissue adhesion solutions across healthcare settings. 

Key Market Trends & Insights

• North America dominated the topical cyanoacrylates market with the largest revenue share of 42.35% in 2024.
• The topical cyanoacrylates market in the U.S. accounted for the largest revenue share of 76.64% in North America in 2024.
• Based on product, the 2-Octyl Cyanoacrylate segment led the market with the largest revenue share in 2024.
• Based on application, the plastic surgery and aesthetic procedures segment is expected to grow at the fastest rate over the forecast period.
• By end use, the hospitals segment led the market with the largest revenue share of 46.58% in 2024.

Market Size & Forecast

• 2024 Market Size: USD 97.5 Million
• 2033 Projected Market Size: USD 160.2 Million
• CAGR (2025-2033): 5.65%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

The rising prevalence of chronic wounds, surgical procedures, and accident-related injuries has significantly boosted the need for effective, fast-acting adhesives that offer secure wound closure with minimal trauma. The topical cyanoacrylates market is driven by several key factors, including the increasing demand for efficient wound closure solutions, the rising prevalence of acute wounds, and the growing adoption of minimally invasive surgical procedures. The increasing burden of wounds, including minor cuts, lacerations, abrasions, and superficial burns, is expected to drive growth in the market. According to The Korean Society of Emergency Medicine, Lacerations continue to be a frequent reason for visits to emergency departments (EDs) in the U.S. They represent about 8.2% of all ED visits, leading to an estimated 7 to 9 million lacerations treated annually across U.S. emergency facilities. Many countries have a substantial population affected by such injuries, creating a strong demand for accessible treatment options. For instance, the National Safety Council, in 2022, around 52,600,000 people suffered nonfatal medically consulted injuries.

The rising incidence of minor burns, often caused by everyday household accidents, occupational hazards, and increased outdoor activities, significantly drives the demand for topical cyanoacrylate products. For instance, the World Health Organization (WHO) estimates that each year, 11 million people sustain burn injuries, with approximately 92% of these being minor burns that are managed in outpatient settings . Similarly, according to a Medscape report from May 2024, around 1.25 million individuals with burn injuries visit emergency departments in the U.S. annually, with approximately 63,000 of these cases involving minor burns. About one-third of these visits for burn injuries occur in emergency departments .

Access Full Report@ https://www.grandviewresearch.com/industry-analysis/topical-cyanoacrylates-market-report

Workplace environments contribute significantly to the burden of acute wounds, which is driving the demand for topical cyanoacrylate products. According to data published by CCD Law in December 2023, approximately 30% of all workplace injuries involve cuts or lacerations, ranging from minor scratches and abrasions to more severe puncture wounds and amputations . In addition, similar trends have been observed in other countries. The Australian Bureau of Statistics reported in February 2023 that nearly 497,300 people had work-related injuries or illnesses in the 2021–2022 fiscal year, with cuts or open wounds. These numbers demonstrate the worldwide impact of acute wounds in workplaces and highlight the strong potential for growth in the topical cyanoacrylates market.

Furthermore, the growing incidence of sports-related injuries is one of the primary driving factors fueling market growth. For instance, according to the National Safety Council (NSC), exercise equipment was associated with approximately 482,886 injuries in 2023, marking it as the leading cause of injuries among all sports and recreation categories .

Innovations and technological advancements have played a crucial role in expanding the applications of topical cyanoacrylates, with the development of formulations that offer improved biocompatibility, enhanced flexibility, and reduced risk of infection. These innovations have also led to the creation of faster-setting, more durable adhesives suitable for a wide range of medical applications. Regulatory developments are equally influential, as stringent approval processes and safety standards ensure the use of high-quality, medical-grade cyanoacrylates, thus fostering market confidence and adoption.

Governments and health authorities are increasingly emphasizing the importance of safe and effective wound management products, which has led to rigorous testing, certification, and compliance protocols. Overall, a combination of technological progress, evolving clinical needs, and regulatory support continues to propel the growth of the topical cyanoacrylates market, encouraging ongoing research and the development of next-generation adhesive solutions.

Key Topical Cyanoacrylates Companies:

The following are the leading companies in the topical cyanoacrylates market. These companies collectively hold the largest market share and dictate industry trends.

• Medline Industries, LP
• Advanced Medical Solutions Group plc
• B. Fuller Medical Adhesive Technologies, LLC
• Meril Life
• Ethicon (Johnson & Johnson MedTech)
• Medtronic
• Alfa Pharma GmbH
• Epiglue Pharma Pvt. Ltd.
• Braun SE
• Resivant Medical LLC.

Recent Developments

• In August 2024, Resivant Medical announced that it had obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for its initial two products: the Cutiva Topical Skin Adhesive and the Cutiva PLUS Skin Closure System, which features an innovative combination of an adhesive mesh patch and high-viscosity Cutiva liquid adhesive.
• In September 2023, Advanced Medical Solutions Group plc announced that it has entered into an agreement with TELA Bio, Inc., a specialist in designing and developing innovative soft-tissue reconstruction solutions aimed at optimizing clinical outcomes, to commercialize LiquiBandFix8 in the U.S.
• In June 2023, LiquiBandFix8/LIQUIFIX received Pre-Market Approval (PMA) from the U.S. Food and Drug Administration (FDA) for use in hernia repair procedures. The device employs drops of cyanoacrylate adhesive rather than traditional metal tacks to secure mesh to tissue during both open and laparoscopic hernia surgeries. As the first product of its kind approved in the U.S., it is expected to benefit patients by offering a less invasive application that may help decrease pain and reduce post-operative complications.
• In May 2023, H.B. Fuller Company, the world's largest pureplay adhesives manufacturer, announced its acquisition of Adhezion Biomedical, a privately owned U.S.-based medical adhesives company. Adhezion Biomedical serves clients in over 40 countries and holds more than 35 international certifications, including 105 patents. The acquisition of Adhezion, which develops and distributes specialized, proprietary cyanoacrylate technologies for surgical procedures, wound care, and infection prevention in healthcare environments, strengthens H.B. Fuller’s position in the topical skin bonding market by establishing a larger, more scalable platform. This move complements the capabilities gained through the company's 2021 purchase of Tissue Seal. It enhances its vertically integrated adhesive manufacturing and packaging capabilities, further expanding its footprint in the medical adhesives sector.
• In February 2023, Advanced Medical Solutions Group plc, a global leader in tissue-healing technologies, announced the acquisition of Connexicon Medical Limited (“Connexicon”), a specialist in tissue adhesive technologies. The deal includes an initial upfront payment of USD 8.07 million, with additional deferred payments linked to the achievement of specific research & development, regulatory, and commercial milestones between 2023 and 2027. This acquisition reinforces AMS’s position in the USD 300 million global tissue adhesive market, broadens its product portfolio, and markedly enhances its technical and R&D capabilities in cyanoacrylate technology .

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.